Skip to content

Bellicum Pharmaceuticals, Inc.

CIK 0001358403

← back to feed
Revenue (TTM)
$2.01M
−75.8% YoY Q3 Nov 2023
Net Income (TTM)
−$23.39M
−157.3% YoY Q3 Nov 2023
EPS Diluted (TTM)
−$0.75
+3.6% YoY Q3 Nov 2023
Gross Margin
83.0%
Q3 Nov 2023
Operating Margin
-1,177.8%
Q3 Nov 2023
Net Margin
-1,165.0%
Q3 Nov 2023
Free Cash Flow (TTM)
−$37.4M
Q3 Nov 2023
Cash
$5.91M
Q3 Nov 2023
Total Debt
$0
Q3 Nov 2023
Shares Outstanding
9.72M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings